NasdaqCM - Nasdaq Real Time Price USD

aTyr Pharma, Inc. (ATYR)

3.2150

-0.0950

(-2.87%)

As of 1:02:27 PM EDT. Market Open.

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced

GlobeNewswire 5 hours ago

ATYR
-2.87%
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and developmen

GlobeNewswire 6 days ago

ATYR
-2.87%
When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit?

We feel now is a pretty good time to analyse aTyr Pharma, Inc.'s ( NASDAQ:ATYR ) business as it appears the company may...

Simply Wall St. 14 days ago

ATYR
-2.87%
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present a poster featuring preclinical data for AT

GlobeNewswire 15 days ago

ATYR
-2.87%
US High Growth Tech Stocks to Watch in 2023

As the U.S. market experiences heightened volatility with major indices like the S&P 500 and Nasdaq Composite closing sharply lower amid tariff concerns, investors are closely monitoring economic indicators that could impact small-cap companies and technology stocks. In such a climate, identifying high-growth tech stocks involves looking for companies that demonstrate resilience through innovation and adaptability to shifting trade policies, making them noteworthy in this unpredictable...

Simply Wall St. last month

MGTX

AKBA

ATYR
-2.87%
aTyr Pharma to Participate in April Investor Conferences

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025. Details of the conferences appear below: Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location:

GlobeNewswire last month

ATYR
-2.87%
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors approved on March 21, 2025 an aggregate of three grants to three employees of nonstatutory stock options to purchase an aggregate of 43,800 shares of aTyr’s commo

GlobeNewswire last month

ATYR
-2.87%
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies

GlobeNewswire last month

ATYR
-2.87%
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...

aTyr Pharma Inc (ATYR) reports robust financial health and significant progress in its pivotal phase three study for pulmonary sarcoidosis.

GuruFocus.com last month

ATYR
-2.87%
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Publication in Science Translational Medicine validates efzofitimod’s mechanism of action. Company to host conference call and webcast today, March 13th at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (

GlobeNewswire last month

ATYR
-2.87%
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor. Scientific insights further strengthen the rationale for clinical program for efzofitimod in interstitial lung disease (ILD). SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro

GlobeNewswire 2 months ago

ATYR
-2.87%
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications.SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the outcome of a fourth, pre-planned interim safety analysis conducted b

GlobeNewswire 2 months ago

ATYR
-2.87%
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Manag

GlobeNewswire 2 months ago

ATYR
-2.87%
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 9 – 12, 2025, in Miami, FL. Details of the presentation appear below:

GlobeNewswire 2 months ago

ATYR
-2.87%
Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, aTyr Pharma...

Simply Wall St. 3 months ago

ATYR
-2.87%
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of

GlobeNewswire 3 months ago

ATYR
-2.87%
Several Insiders Invested In aTyr Pharma Flagging Positive News

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. 4 months ago

ATYR
-2.87%
Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts.

Simply Wall St. 4 months ago

VNDA

ATYR
-2.87%

KNSA
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%

Key Insights Significantly high institutional ownership implies aTyr Pharma's stock price is sensitive to their trading...

Simply Wall St. 4 months ago

ATYR
-2.87%
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA. Details of the presentation app

GlobeNewswire 4 months ago

ATYR
-2.87%

Performance Overview

Return	ATYR	S&P 500 (^GSPC)
YTD	-11.19%	+0.12%
1-Year	+76.65%	+12.23%
3-Year	+5.07%	+46.34%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

aTyr Pharma, Inc. (ATYR)

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit?

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

US High Growth Tech Stocks to Watch in 2023

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Several Insiders Invested In aTyr Pharma Flagging Positive News

Exploring Three High Growth Tech Stocks In The United States

aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview